New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:51 EDTIDRAIdera candidate IMO-8400 likely to be failed drug, says Summer Street
Summer Street predicts Idera Pharmaceuticals' IMO-8400, a small-molecule toll-like receptor antagonist being tested as a treatment for psoriasis, will be a failed drug candidate. The firm says Idera is developing a third-generation product, IMO-9200, which indicates the company has low expectations for IMO-8400.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
07:09 EDTIDRAVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 17, 2015
06:22 EDTIDRAPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use